# Allogene Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allogene-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.allogene.com
- Total disclosed funding: $412M
- Latest round: Series A (Apr 9, 2018)
- Investors on record: 7

## About

Allogene Therapeutics, Inc. is a biotechnology company focused on developing innovative allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for the treatment of blood cancers and autoimmune diseases.Allogene Therapeutics was founded in 2018 and is headquartered in South San Francisco, US. The company specializes in the development of AlloCAR T™ products. Founded by Arie Belldegrun, Allogene has raised a total of USD 550.00 mn across multiple funding rounds, with the most recent funding, a Private Placement/Follow on, amounting to USD 550.00 mn occurring on October 10, 2018.Allogene Therapeutics develops investigational AlloCAR T™ products, including ALLO-501, designed to treat relapsed/refractory non-Hodgkin lymphoma, and ALLO-329, aimed at autoimmune diseases such as lupus and scleroderma. The company’s therapies are engineered for immediate patient access, eliminating complex logistics associated with traditional methods. These products are currently undergoing clinical trials in the United States as well as select international markets including Europe and Canada.In the most recent year, Allogene Therapeutics reported revenue of USD 22,000. The company's financial framework includes revenue generation through partnerships, licensing agreements, and clinical trial collaborations, focusing on milestone payments and royalties from their flagship products as they advance through clinical development.Allogene Therapeutics aims to expand its product pipeline focusing on AlloCAR T™ therapies targeting various cancer types and autoimmune disorders. The company plans to broaden its market reach into Europe and Canada by 2024, leveraging the recent funding of USD 550.00 mn raised to support ongoing research and development initiatives. This funding will facilitate the advancement of clinical trials and the commercialization of its products, ensuring readiness for market entry.

## Funding rounds

- Series A, Apr 9, 2018, $412M — TPG, Pfizer Inc., Gilead Sciences, Inc., The University of California Office of the Chief Investment Officer, Vida Ventures, Two River, Bellco Capital

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series A
- Pfizer Inc. — Series A
- Gilead Sciences, Inc. — Series A
- The University of California Office of the Chief Investment Officer — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A
- Two River (https://capitalatlas.ai/funds/two-river) — Series A
- Bellco Capital (https://capitalatlas.ai/funds/bellco-capital) — Series A